---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-019671"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T15:39:42.149578+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Collegium prices $241.5M convertible notes offering, repurchases $117.4M of 2026 notes

## Summary
- Priced $210M convertible notes offering, upsized to $241.5M with full exercise of initial purchasers' option.
- Notes bear 2.875% interest, mature Feb 2029; initial conversion price $36.56/share, ~30% premium to $28.12.
- Net proceeds estimated at $203.2M ($233.8M if greenshoe fully exercised) after discounts and expenses.
- Used $140.1M to repurchase $117.4M of its 2.625% convertible notes due 2026.
- Remainder for general corporate purposes including business development and capital allocation.

## SEC filing metadata
- accession: 0001104659-23-019671
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/tm235915d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-019671
- JSON: https://secwatch.observer/filing/0001104659-23-019671.json
- Plain text: https://secwatch.observer/filing/0001104659-23-019671.txt

## Key facts
- Debt Financings
  COLLEGIUM PHARMACEUTICAL, INC incurred convertible notes of $241,500,000 principal amount with The Bank of New York Mellon Trust Company, N.A. at 2.875% per annum maturing February 15, 2029.
  - Instrument: convertible notes
  - Principal: $241,500,000 principal amount
  - Counterparty: The Bank of New York Mellon Trust Company, N.A.
  - Rate: 2.875% per annum
  - Maturity: February 15, 2029
  - Event: incurrence
  source text: On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm
- Material Agreements
  COLLEGIUM PHARMACEUTICAL, INC entered into 2.875% Convertible Senior Notes due 2029 Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029 (effective 2023-02-10).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: The Bank of New York Mellon Trust Company, N.A.
  - Value: $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029
  - Effective: 2023-02-10
  source text: On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of February 10, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “ Trustee ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.